fludeoxyglucose F 18 (Moffitt Cancer Center)

**Fludeoxyglucose F 18** is a fluorine-18-labeled glucose analogue and positron-emitting radiopharmaceutical used for PET imaging. It enters cells through facilitative glucose transporters and is phosphorylated to FDG-6-phosphate, which is retained intracellularly because it is not substantially further metabolized; PET therefore visualizes regional glucose uptake and metabolism. Moffitt Cancer Center evaluated FDG-labeled autologous erythrocytes in a withdrawn early-phase study of PET-CT-based cardiac ejection-fraction monitoring in patients with breast cancer receiving neoadjuvant chemotherapy. Standard fludeoxyglucose F 18 injection is an FDA-approved intravenous PET imaging agent for oncology, cardiology, and neurology applications. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03295695))

Other names

18F-FDG18FDG2-deoxy-2-[18F]fluoro-D-glucose2-[18F]fluoro-2-deoxy-D-glucoseFDGfluorine F 18-fludeoxyglucosefluorodeoxyglucose F 18